Seborrhoeic dermatitis: Current treatment practices

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 8, 2004, Pages 1755-1765

  Gupta, Aditya K ^a,b,c   Kogan, Nataly ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MEDIPROBE RESEARCH INC   (Canada)

^c NONE   (Canada)

Author keywords

Seborrhoeic dermatitis; Treatment

Indexed keywords

ALLYLAMINE; ANTIFUNGAL AGENT; BETAMETHASONE VALERATE; BIFONAZOLE; CALCIPOTRIOL; CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN; DESONIDE; HYDROCORTISONE; ITRACONAZOLE; KERATOLYTIC AGENT; KETOCONAZOLE; LITHIUM; LITHIUM GLUCONATE; METRONIDAZOLE; PIMECROLIMUS; PLACEBO; PYRIDONE DERIVATIVE; PYRITHIONE ZINC; SALICYLIC ACID; SELENIUM SULFIDE; SHAMPOO; STEROID; SUCCINATE LITHIUM; TACROLIMUS; TERBINAFINE; UREA;

CHRONIC DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; FACE; HUMAN; IMMUNE RESPONSE; LIVER TOXICITY; MALASSEZIA; RECURRENT DISEASE; REVIEW; SCALP; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ATROPHY; SKIN INFLAMMATION; SKIN IRRITATION; THORAX;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTIFUNGAL AGENTS; CALCITRIOL; DERMATITIS, SEBORRHEIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LITHIUM; MALASSEZIA; ULTRAVIOLET THERAPY;

EID: 4344652231     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.8.1755     Document Type: Review

References (122)

1. UNNA PG: Notice. Monatschr. Prakt. Dermatol. (1891) 13:225-237.
2. GUPTA A, BLUHM R: Seborrheic dermatitis. J. Eur. Acad. Dermatol. Venereol. (2004) 18(1):13-26.
3. GUPTA AK, MADZIA SE, BATRA R: Etiology and management of Seborrheic dermatitis. Dermatology (2004) 208(2):89-93.
4. IVE FA, PAYNE R: Seborrhoeic dermatitis. In: Superficial fungal Infections. Verbov J (Ed.). MTP Press, Lancaster (1986):73-87.
5. HAY RJ, GRAHAM-BROWN RA: Dandruff and seborrhoeic dermatitis: causes and management. Clin. Exp. Dermatol. (1997) 2200-6.
6. BURTON JL: Seborrheic dermatitis. In: Textbook of Dermatology. Wilkinson DS, Ebling FJG (Eds), Blackwell Scientific Publications, Oxford, UK (1992):1561-1622.
7. FAERGEMANN J: Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br. J. Dermatol. (1986) 114(6):695-700.
8. FAERGEMANN J: Management of seborrheic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatol. (2000) 1(2):75-80.
9. PIERARD-FRANCHIMONT C, HERMANNS JF, DEGREEF H, PIERARD GE: From axioms to new insights into dandruff. Dermatology (2000) 200(2):93-98.
10. FARTHING CF, STAUGHTON RC, ROWLAND PAYNE CM: Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease. Clin. Exp. Dermatol. (1985) 10(1):3-12.
11. SMITH KJ, SKELTON HG, YEAGER J et al.: Cutaneous findings in HIV-1-positive patients: a 42-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J. Am. Acad. Dermatol. (1994) 31(5 Pt 1):746-754.
12. MCCULLEY JP, DOUGHERTY JM, DENEAU DG: Classification of chronic blepharitis. Ophthalmology (1982) 89(10):1173-1180.
13. MCCULLEY JP, DOUGHERTY JM: Blepharitis associated with acne rosacea and seborrheic dermatitis. Int. Ophthalmol. Clin. (1985) 25(1):159-172.
14. REISNER RM: Acne vulgaris. Pediatr. Clin. North Am. (1973) 20(4):851-864.
15. ZUG KA, PALAY DA, ROCK B: Dermatologic diagnosis and treatment of itchy red eyelids. Surv. Ophthalmol. (1996) 40(4):293-306.
16. SABOURAUD R: Diagnosis and treatment of scalp disorders [in French]. (1932):156-169.
17. SHUSTER S: The aetiology of dandruff and the mode of action of therapeutic agents. Br. J. Dermatol. (1984) 111(2):235-242.
18. ARRESE JE, PIERARD-FRANCHIMONT C, DE DONCKER P et al.: Effect of ketoconazole-medicated shampoos on squamometry and Malassezia ovalis load in pityriasis capitis. Cutis (1996) 58(3):235-237.
19. HENG MC, HENDERSON CL, BARKER DC, HABERFELDE G: Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J. Am. Acad. Dermatol. (1990) 23(1):82-86.
20. MCGINLEY KJ, LEYDEN JJ, MARPLES RR, KLIGMAN AM: Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J. Invest. Dermatol. (1975) 64(6):401-405.
21. EICHSTEDT E: Fungal structures in pityriasis vesicolor [in German]. Froriep Neue Notiz Natur Heilk (1846) 39:270.
22. GUPTA AK, KOHLI Y, SUMMERBELL RC, FAERGEMANN J: Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med. Mycol. (2001) 39(3):243-251.
23. BERGBRANT IM, FAERGEMANN J: Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm. Venereol. (1989) 69(4):332-335.
24. BERGBRANT IM, JOHANSSON S, ROBBINS D et al.: The evaluation of various methods and antigens for the detection of antibodies against Pityrosporum ovale in patients with seborrhoeic dermatitis. Clin. Exp. Dermatol. (1991) 16(5):339-343.
25. BERGBRANT IM, JOHANSSON S, ROBBINS D et al.: An immunological study in patients with seborrhoeic dermatitis. Clin. Exp. Dermatol. (1991) 16(5):331-338.
26. KUPPER TS: The role of epidermal cytokines. In: Immunophysiology: the role of cells and cytokines in immunity and inflammation. Shevach E, Oppenheim J (Eds), Oxford University Press, New York, USA (1990):285-305.
27. CATTERALL MD, WARD ME, JACOBS P: A reappraisal of the role of Pityrosporum orbiculare in pityriasis versicolor and the significance of extracellular lipase. J. Invest. Dermatol. (1978) 71(6):398-401.
28. MIDGLEY G, HAY RJ: Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and western blotting. Bull. Soc. Fr. Mycol. Med. (1988) 17:267-276.
29. KIEFFER M, BERGBRANT IM, FAERGEMANN J et al.: Immune reactions to Pityrosporum ovale in adult patients with atopic and seborrheic dermatitis. J. Am. Acad. Dermatol. (1990) 22(5 Pt 1):739-742.
30. ASHBEE HR, INGHAM E, HOLLAND KT, CUNLIFFE WJ: Cell-mediated immune responses to Malassezia furfur serovars A, B and C in patients with pityriasis versicolor, seborrheic dermatitis and controls. Exp. Dermatol. (1994) 3(3):106-112.
31. NEUBER K, KROGER S, GRUSECK E, ABECK D, RING J: Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch. Dermatol. Res. (1996) 288(9):532-536.
32. PARRY ME, SHARPE GR: Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br. J. Dermatol, (1998) 139(2):254-263.
33. BERGBRANT IM: Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm. Venereol. Suppl. (Stockh) (1991) 167:1-36.
34. HALE EK, BYSTRYN JC: Relation between skin temperature and location of facial lesions in seborrheic dermatitis. Arch. Dermatol. (2000) 136(4):559-560.
35. REBORA A, RONGIOLETTI F: The red face: seborrheic dermatitis. Clin. Dermatol. (1993) 11(2):243-251.
36. PECHERE M, KRISCHER J, REMONDAT C et al.: Malassezia spp carriage in patients with seborrheic dermatitis. J. Dermatol. (1999) 26(9):558-561.
37. PIERARD-FRANCHIMONT C, WILLEMAERS V, FRAITURE AL, PIERARD GE: Squamometry in seborrheic dermatitis. Int. J. Dermatol. (1999) 38(9):712-715.
38. SHEMER A, NATHANSOHN N, KAPLAN B et al.: Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int. J. Dermatol. (2000) 39(7):532-534.
39. ABECK D: Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrheic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int. J. Dermatol. (2004) (In Press).
40. JUE SG, DAWSON GW, BROGDEN RN: Ciclopirox olamine 1% cream. A preliminary review of its antimicrobial activity and therapeutic use. Drugs (1985) 29(4):330-341.
41. KORTING HC, GRUNDMANN-KOLLMANN M: The hydroxypyridones: a class of antimycotics of its own. Mycoses (1997) 40(7-8):243-247.
42. UNHOLZER A, VARIGOS G, NICHOLLS D et al.: Ciclopiroxolamine cream for treating seborrheic dermatitis: a double-blind parallel group comparison. Infection (2002) 30(6):373-376.
43. ABDEL-RAHMAN SM, NAHATA MC: Oral terbinafine: a new antifungal agent. Ann. Pharmacother. (1997) 31(4):445-456.
44. FAERGEMANN J: Treatment of seborrhoeic dermatitis with oral terbinafine? Lancet (2001) 358(9277):170.
45. FOURNIER J, EMERIT J, MICHELSON AM: [Peroxidation of lipids in the inflammatory process]. C. R. Seances Acad. Sci. D. (1980) 291(9):753-755.
46. MARKS R, PEARSE AD, WALKER AP: The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br. J. Dermatol. (1985) 112(4):415-422.
47. SCHMID MH, KORTING HC: Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Dermatology (1996) 193(1):1-5.
48. MCGRATH J, MURPHY GM: The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs (1991) 41(2):178-184.
49. PIERARD-FRANCHIMONT C, GOFFIN V, DECROIX J, PIERARD GE: A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol. Appl. Skin Physiol. (2002) 15(6):434-441.
50. PIERARD-FRANCHIMONT C, PIERARD GE: A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology (2002) 204(4):344-347.
51. ERMOLAYEVA E, SANDERS D: Mechanism of pyrithione-induced membrane depolarization in Neurospora crassa. Appl. Environ. Microbiol. (1995) 61(9):3385-3390.
52. LACKNER TE, CLISSOLD SP: Bifonazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Drugs (1989) 38(2):204-225.
53. HEGEMANN L, TOSO SM, LAHIJANI KI, WEBSTER GF, UITTO J: Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J. Invest. Dermatol. (1993) 100(3):343-346.
54. BREMM KD, PLEMPEL M: Modulation of leukotriene metabolism from human polymorphonuclear granulocytes by bifonazole. Mycoses (1991) 34(1-2):41-45.
55. VAN ERP PE, VAN DE KERKHOF PC: Calmodulin levels in psoriasis and other skin disorders. Arch. Dermatol. Res. (1987) 279(3):151-153.
56. HAGEMANN I, PROKSCH E: Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm. Venereol. (1996) 76(5):353-356.
57. KUSTER W, BOHNSACK K, RIPPKE F et al.: Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. Dermatology (1998) 196(2):217-222.
58. WOHLRAB W: The influence of urea on the penetration kinetics of topically applied corticosteroids. Acta Derm. Venereol. (1984) 64(3):233-238.
59. PARSAD D, PANDHI R, NEGI KS, KUMAR B: Topical metronidazole in seborrheic dermatitis-a double-blind study. Dermatology (2001) 202(1):35-37.
60. KOCA R, ALTINYAZAR HC, ESTURK E: Is topical metronidazole effective in seborrheic dermatitis? A double-blind study. Int. J. Dermatol. (2003) 42(8):632-635.
61. CAMERA E, CANNISTRACI C, BRIGANTI S, COLOMBO D, PICARDO M: Scavenging effects of terbinafine on free radicals in vitro. Br. J. Dermatol. (1999) 140(4):640-644.
62. ROSEN T, SCHELL BJ, ORENGO I: Anti-inflammatory activity of antifungal preparation. Int. J. Dermatol. (1997) 36(10):788-792.
63. COWLEY NC, FARR PM, SHUSTER S: The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br. J. Dermatol. (1990) 122(1):71-76.
64. CORTE M, JUNG K, LINKER U et al.: [Topical application of a 0.1% ciclopiroxolamine solution for the treatment of pityriasis versicolor]. Mycoses (1989) 32(4):200-203.
65. HANEL H, SMITH-KURTZ E, PASTOWSKY S: [Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect]. Mycoses (1991) 34(Suppl. 1):91-93.
66. GOUDARD M, REGLI P, LUBRANO N: [In vitro antifungal spectrum of ciclopiroxolamine]. Pathol. Biol. (Paris) (1989) 37(5 Pt 2):621-623.
67. SQUIRE RA, GOODE K: A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J. Dermatolog. Treat. (2002) 13(2):51-60.
68. ALY R, KATZ HI, KEMPERS SE et al.: Ciclopirox gel for seborrheic dermatitis of the scalp. Int. J. Dermatol. (2003) 42(Suppl. 1): 19-22.
69. ALTMEYER P: Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double blind, vehicle-controlled trial. Int. J. Dermatol. (2004) (In Press).
70. LEBWOHL M, PLOTT T: Safety and efficacy of cilcopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int. J. Dermatol. (2004) (In Press).
71. FORD GP, FARR PM, IVE FA, SHUSTER S: The response of seborrhoeic dermatitis to ketoconazole. Br. J. Dermatol. (1984) 111(5):603-607.
72. SEHGAL VN, KHANDPUR S: Antifungal agents: unapproved uses, dosages, or indications. Clin. Dermatol. (2002) 20(5):481-489.
73. LEEMING JP, SANSOM JE, BURTON JL: Susceptibility of Malassezia furfur subgroups to terbinafine. Br. J. Dermatol. (1997) 137(5):764-767.
74. VILLARS VV, JONES TC: Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br. J. Dermatol. (1992) 126(Suppl. 39):61-69.
75. GUPTA AK, KOHLI Y: In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br. J. Dermatol. (2003) 149(2):296-305.
76. FREEMAN S, HOWARD A, FOLEY P et al.: Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. Australas. J. Dermatol. (2002) 43(3):186-189.
77. FRANZ TJ, PARSELL DA, HALUALANI RM et al.: Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int. J. Dermatol. (1999) 38(8):628-632.
78. CHRISTODOULOU GN, GEORGALA S, VARELTZIDES A, CATSAROU A: Lithium in seborrheic dermatitis. Psychiatr. J. Univ. Ott. (1983) 8(1):27-29.
79. EFALITH MULTICENTER TRIAL GROUP: A double-blind, placebo-controlled, multicenter trial of lithium succinate ointment in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol. (1992) 26(3 Pt 2):452-457.
80. DRENO B, MOYSE D: Lithium gluconate in the treatment of seborrhoeic dermatitis: a multicenter, randomised, double-blind study versus placebo. Eur. J. Dermatol. (2002) 12(6):549-552.
81. SCAPARRO E, QUADRI G, VIRNO G, ORIFICI C, MILANI M: Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br. J. Dermatol. (2001) 144(4):854-857.
82. LEEMING JP, BURTON JL: Lithium succinate and seborrhoeic dermatitis: an antifungal mode of action? Br. J. Dermatol. (1990) 122(5):718-719.
83. NENOFF P, HAUSTEIN UF, MUNZBERGER C: In vitro activity of lithium succinate against Malassezia furfur. Dermatology (1995) 190(1):48-50.
84. HORROBIN DF: Effects of lithium on essential fatty acid and prostaglandin metabolism. In: Lithium and cell physiology. Springer-Verlog, New York, USA (1990):137-49.
85. MAES M, SONG C, LIN AH et al.: In vitro immunoregulatory effects of lithium in healthy volunteers. Psychopharmacology (Berl) (1999) 143(4):401-407.
86. OCKENFELS HM, WAGNER SN, KEIM-MAAS C et al.: Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. Arch. Dermatol. Res. (1996) 288(4):173-178.
87. DRENO B, CHOSIDOW O, REVUZ J, MOYSE D: Lithium gluconate 8% versus ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study. Br. J. Dermatol. (2003) 148(6):1230-1236.
88. CRUTCHFIELD CE, III: Pimecrolimus; a new treatment for seborrheic dermatitis. Cutis (2002) 70(4):207-208.
89. BROWNELL I, QUAN LT, HSU S: Topical pimecrolimus in the treatment of seborrheic dermatitis. Dermatol. Online J. (2003) 9(3):13.
90. BORNHOVD E, BURGDORF WH, WOLLENBERG A: Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J. Am. Acad. Dermatol. (2001) 45(5):736-743.
91. LEMSTER BH, CARROLL PB, RILO HR et al.: IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin. Exp. Immunol. (1995) 99(2):148-154.
92. MORI A, SUKO M, NISHIZAKI Y et al.: Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoid. Int. Arch. Allergy Immunol. (1994) 104(Suppl, 1):32-35.
93. NAKAGAWA H, ETOH T, ISHIBASHI Y et al.: Tacrolimus ointment for atopic dermatitis. Lancet (1994) 344(8926):883.
94. RUZICKA T, BIEBER T, SCHOPF E et al.: A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N. Engl. J. Med. (1997) 337(12):816-821.
95. MEINGASSNER JG, STUTZ A: Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J. Invest. Dermatol. (1992) 98(6):851-855.
96. SENGOKU T, MORITA K, SATO S et al.: [Effects of tacrolimus ointment on Type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice]. Nippon Yakurigaku Zasshi (1998) 112(3):221-232.
97. KRAGBALLE K, GJERTSEN BT, DE HOOP D et al.: Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet (1991) 337(8735):193-196.
98. BERTH-JONES J, HUTCHINSON PE: Vitamin D analogues and psoriasis. Br. J. Dermatol. (1992) 127(2):71-78.
99. JENSEN AM, LLADO MB, SKOV L et al.: Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br. J. Dermatol. (1998) 139(6):984-991.
100. KRAGBALLE K, IVERSEN L: Calcipotriol. A new topical antipsoriatic. Dermatol. Clin. (1993) 11(1):137-141.
101. BASAK PY, ERGIN S: Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp. J. Eur. Acad. Dermatol. Venereol. (2001) 15(1):86-88.
102. DE MARE S, DE JONG EG, VAN DE KERKHOF PC: DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone. Br. J. Dermatol. (1990) 123(3):291-295.
103. BERG M: Epidemiological studies of the influence of sunlight on the skin. Photodermatology (1989) 6(2):80-84.
104. DAHL KB, REYMANN F: Photochemotherapy in erythrodermic seborrhoic dermatitis. Arch. Dermatol. (1977) 113(9):1295-1296.
105. SALO O, LASSUS A, JUVAKOSKI T, KANERVA L, LAUHARANTA J: [Treatment of atopic dermatitis and seborrheic dermatitis with selective UV-phototherapy and PUVA. A comparative study]. Dermatol. Monatsschr. (1983) 169(6):371-375.
106. DUTHIE MS, KIMBER I, NORVAL M: The effects of ultraviolet radiation on the human immune system. Br. J. Dermatol. (1999) 140(6):995-1009.
107. EL GHORR AA, NORVAL M: Biological effects of narrow-band (311 nm TL01) UVB irradiation: a review. J. Photochem. Photobiol. B (1997) 38(2-3):99-106.
108. VIAC J, GOUJON C, MISERY L et al.: Effect of UVB 311 nm irradiation on normal human skin. Photodermatol. Photoimmunol. Photomed. (1997) 13(3):103-108.
109. MOEHRLE M, DENNENMOSER B, SCHLAGENHAUFF B, THOMMA S, GARBE C: High prevalence of seborrhoeic dermatitis on the face and scalp in mountain guides. Dermatology (2000) 201(2):146-147.
110. PETER RU, RICHARZ-BARTHAUER U: Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br. J. Dermatol. (1995) 132(3):441-445.
111. SKINNER RB, JR., NOAH PW, TAYLOR RM et al.: Double-blind treatment of seborrheic dermatitis with 2% ketoconazole cream. J. Am. Acad. Dermatol. (1985) 12(5 Pt 1):852-856.
112. STRATIGOS JD, ANTONIOU C, KATSAMBAS A et al.: Ketoconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. A double-blind comparative study. J. Am. Acad. Dermatol. (1988) 19(5 Pt 1):850-853.
113. FAERGEMANN J: Treatment of seborrhoeic dermatitis of the scalp with ketoconazole shampoo. A double-blind study. Acta Derm. Venereol. (1990) 70(2):171-172.
114. DUPUY P, MAURETTE C, AMORIC JC, CHOSIDOW O: Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br. J. Dermatol, (2001) 144(5):1033-1037.
115. CHOSIDOW O, MAURETTE C, DUPUY P: Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology (2003) 206(3):233-240.
116. BAYSAL V, YILDIRIM M, OZCANLI C, CEYHAN AM: Itraconazole in the treatment of seborrheic dermatitis: a new treatment modality. Int. J. Dermatol. (2004) 43(1):63-66.
117. CAPUTO R, BARBARESCHI M: Itraconazole: new horizons. Giornale Itlaiano di dermatologia e venereologia. Giornale Itlaiano di dermatologiae venereologia (2002) 137:1-7.
118. CASSANO NMD, AMORUSO AMD, LOCONSOLE FMD, VENA GAMD: Oral terbinafine for the treatment of seborrheic dermatitis in adults. Int. J. Dermatol. (2002) 41(11):821-822.
119. MILANI M, ANTONIO DM, GRAMAZIO R et al.: Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curr. Med. Res. Opin. (2003) 19(4):342-345.
120. MESHKINPOUR A, SUN J, WEINSTEIN G: An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J. Am. Acad. Dermatol. (2003) 49(1):145-147.
121. BRAZA TJ, DICARLO JB, SOON SL, MCCALL CO: Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br. J. Dermatol. (2003) 148(6):1242-1244.
122. BERTH-JONES J, ADNITT PI: Topical calcipotriol is not effective in facial seborrhoeic dermatitis. J. Dermatolog. Treat. (2001) 12(3):179.